Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
5.82
-0.15 (-2.51%)
At close: Sep 15, 2026, 4:00 PM EDT
5.77
-0.05 (-0.86%)
After-hours: Sep 15, 2026, 7:49 PM EDT
Opus Genetics Employees
As of December 31, 2025, Opus Genetics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 10 or 55.56% compared to the previous year.
Employees
28
Change (1Y)
10
Growth (1Y)
55.56%
Revenue / Employee
$352,000
Profits / Employee
-$3,843,214
Market Cap
484.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 28 | 10 | 55.56% | 27 | 1 |
| Dec 31, 2024 | 18 | 4 | 28.57% | 18 | 0 |
| Dec 31, 2023 | 14 | 5 | 55.56% | 14 | 0 |
| Dec 31, 2022 | 9 | 1 | 12.50% | 9 | 0 |
| Dec 31, 2021 | 8 | 3 | 60.00% | 8 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Capricor Therapeutics | 231 |
| ARS Pharmaceuticals | 200 |
| Puma Biotechnology | 179 |
| Artiva Biotherapeutics | 115 |
| Prelude Therapeutics | 79 |
| Zura Bio | 40 |
| Ovid Therapeutics | 23 |
IRD News
- 6 days ago - Opus Genetics price target raised to $14 from $11 at Leerink - TheFly
- 6 days ago - Opus Genetics price target raised to $20 from $10 at Oppenheimer - TheFly
- 6 days ago - Opus Genetics price target raised to $16 from $13 at Chardan - TheFly
- 6 days ago - Opus Genetics Transcript: Study result - Transcripts
- 6 days ago - Opus Genetics Slides: Study result - Filings
- 6 days ago - Opus Genetics Press release: Study result - Filings
- 6 days ago - Opus Genetics announces results from low-dose Cohort 1 of BIRD-1 trial - TheFly
- 6 days ago - Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 - GlobeNewsWire